ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

THE ASSESSMENT AMONG INTRATHECAL ISOBARIC LEVOBUPIVACAINE 0.6% ALSO ISOBARIC ROPIVACAINE 0.6% IN INFERIOR LIMB OPERATIONS

AUTHORS:

Dr Kiran Waseem, Dr Tazmeen Qureshi, Dr. Hafiz Eice Muhammad

ABSTRACT:

Background & Objectives: Levobupivacaine also ropivacaine remain 2 lately presented local anesthetics replacements to bupivacaine in medical rehearsal. The current research was led to associate effectiveness of intrathecal isobaric levobupivacaine 0.6% also isobaric ropivacaine 0.6% in rapports of sensory also motor blockade features, intraoperative hemodynamics constancy also side effects if any. Methodology: Our current research was conducted at Sir Ganga Ram Hospital Lahore Pakistan from August 2018 to May 2019. The potential randomized binary blind research stayed led in 70 ASA mark 1-2 cases in age sets of 19-65 years experiencing inferior limb operations. Cases remained alienated in 3 sets of 35 cases every. Set L established 4 ml isobaric levobupivacaine 0.6%, while cases in Set R established 4 ml isobaric ropivacaine intrathecally. Cases remained measured for beginning also period of sensory & motor obstruction, intraoperative hemodynamic limitations & side effects. Results: Here remained not any variance in demographic information, beginning also highest consequence of sensory & motor block in mutually sets (p > 0.06). Period of sensory also motor block & time to 2 section reversion stayed suggestively lengthier in Set L as compared to Set R (p < 0.002). Intraoperative hemodynamic limitations displayed not any statistical implication in mutually sets deprived of any considerable side effects. Conclusion: Researchers accomplish that mutually levobupivacaine & ropivacaine remain active by steady hemodynamics deprived of substantial side effects once exercised intrathecally. Ropivacaine had petite period of sensory & motor blockade as compared to levobupivacaine. Key words: Isobaric; Levobupivacaine; Ropivacaine; SA.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.